Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe Sandoz | en

Choose Location

  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
  • Argentina | es
  • Brazil | pt
  • Canada | en
  • Canada | fr
  • Mexico | es
  • United States | en
  • Australia | en
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Bulgaria | bg
  • Croatia | hr
  • Czech Republic | cs
  • Denmark | da
  • Finland | fi
  • France | fr
  • Germany | de
  • Hungary | hu
  • Italy | it
  • Netherlands | nl
  • Norway | no
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • United Kingdom | en
  • Global | en
  • Sandoz | en
  • Saudi Arabia | ar
  • Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Sandoz

Choose Location

Americas Asia Pacific Europe International Middle East & Africa
  • Argentina | es
  • Australia | en
  • Austria | de
  • Belgium | fr
  • Belgium | nl
  • Brazil | pt
  • Bulgaria | bg
  • Canada | en
  • Canada | fr
  • Croatia | hr
  • Czech Republic | cs
  • Denmark | da
  • Finland | fi
  • France | fr
  • Germany | de
  • Hungary | hu
  • Italy | it
  • Japan | ja
  • Korea | ko
  • Mainland China | zh
  • Mexico | es
  • Netherlands | nl
  • Norway | no
  • Global | en
  • Sandoz | en
  • Poland | pl
  • Portugal | pt
  • Romania | ro
  • Russia | ru
  • Saudi Arabia | ar
  • Slovakia | sk
  • Spain | es
  • Sweden | sv
  • Switzerland | de
  • Switzerland | fr
  • Turkey | tr
  • United Kingdom | en
  • United States | en
    • About Sandoz 
      • Our Purpose and Ambition 
      • What We Do 
      • Innovation, Quality and Supply 
      • Corporate Responsibility 
        • Ethics, Risk and Compliance 
        • Sandoz external funding 
        • Malaria Initiative 
        • Novartis Access 
        • World Child Cancer 
      • Our History 
      • Investor Information 
      A girl with a flower About Sandoz
    • Products & Services 
      • Disease Areas 
        • Anti-Infectives 
        • Respiratory 
        • Endocrinology 
        • Immunology 
        • Oncology 
      • Biopharmaceuticals 
        • Sandoz Biosimilars 
        • Sandoz Biosimilar Portfolio and Pipeline 
        • About Biologics 
        • Development of Biosimilars 
        • Information for Patients 
      • Prescription Medicines 
      • Over-The-Counter Medicines 
      • Partnerships and Collaborations 
        • Biotech Cooperations 
        • Business to Business (B2B) 
        • Biotech Cooperations 
        • Business to Business (B2B) 
        • Business to Business (B2B) 
      00181_300dpi_RGB Products & Services
    • People & Culture 
      • Sandoz Leadership 
        • Richard Saynor 
        • Francisco Ballester 
        • Martin Bischof 
        • Colin Bond 
        • Pierre Bourdage 
        • Valerie Chew 
        • Claire D'Abreu-Hayling 
        • Glenn A. Gerecke, PhD 
        • Rebecca Guntern 
        • Keren Haruvi 
        • Steffen Kurzawa 
        • Inge Maes 
        • Ingrid Sollerer 
      • Diversity & Inclusion 
      • Associate Stories 
    • Investors & Media 
      • Sandoz spin-off 
      • Media Releases 
      • Media Library 
      • Media Contacts 
      • Novartis Annual Reporting Suite 
    • Careers 
      • Working at Sandoz 
      • Diversity & Inclusion 
      • Associate Stories 
      • Job Search 
      • Our Teams 
        • Sandoz Technology 
        • Sandoz People & Organization 
      Sandoz Careers Careers
    • News 
      • News Archive 
      • Media Releases 
      • Publications 
      • Stay Up-To-Date 
      A photo of people in a meeting hall News
    • Contacts 
    working at sandoz Home
Header
Flipping Through Presentation

Investors & Media

Previous Next
White Sandoz logo on blue background

Sandoz spin-off

Novartis has announced an intention to separate the Sandoz business to create a standalone company by way of a 100% spin-off.

Read more

Latest News

Mar 21, 2023

Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

Mar 09, 2023

Sandoz signs Memorandum of Understanding to build new biologics production plant in Slovenia, to support increasing global demand for biosimilar medicines

Feb 20, 2023

Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors

View More

Media Releases

Find announcements about Sandoz products, programs and company updates.

Media Library

Visit the Sandoz media resource center to view and download media resources including documents, images and videos.

Media Contacts

Find contacts at Sandoz for media and journalist inquiries.

Novartis Annual Reporting Suite

Access and download our integrated report, annual regulatory filings, and other disclosures.

Novartis Financial Data

Novartis provides the following information on the Group's strong financial performance since its creation in 1996.

Sandoz Leadership
Sandoz Biosimilar Portfolio and Pipeline

Sandoz Global

Key resources
  • Patients & Caregivers
  • Job seekers
  • Investors
  • Media
Recent updates
  • Sandoz spin-off
Explore
  • Contacts
  • Locations
  • Biosimilar Portfolio and Pipeline
Sandoz Companies
  • 1A Pharma
  • Hexal
  • Lek
Footer Bottom
© 2023 Sandoz International GmbH
  • Terms of Use
  • Privacy Policy
  • About Cookies
  • Legal Notice
  • Social Media Community Guidelines
  • Cookie Settings
  • Site Map
  • Web Accessibility
Novartis Site Directory
This site is intended for a global audience